Cik daudz dividendes maksā Recordati Industria Chimica e Farmaceutica SpA 2024?
Saskaņā ar aktuālo informāciju no novembris 2024, Recordati Industria Chimica e Farmaceutica SpA pēdējo 12 mēnešu laikā izmaksāja kopējo dividendes summu 1,17 EUR pro akciju. Pie pašreizējā Recordati Industria Chimica e Farmaceutica SpA kursa 52,05 EUR, tas atbilst dividendes ienesīgumam 2,25 %.
Dividendes tiek izmaksātas 2 reizes gadā.
2,25 % Dividends rendite | = | 1,17 EUR Dividende | 52,05 EUR akciju cena |
|
Vai Recordati Industria Chimica e Farmaceutica SpA dividende ir droša?
Recordati Industria Chimica e Farmaceutica SpA palielina dividendes jau 11 gadus.
Pēdējo 10 gadu laikā Recordati Industria Chimica e Farmaceutica SpA ir paaugstināts to par 13,842 % gadā.
Pēdējo piecu gadu laikā izmaksas palielinājās par 5,862 %.
Analisti prognozē, ka šajā tekošajā finanšu gadā gaidāms Dividendu pieaugums aptuveni 3,432%.
Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse
Ko dara Recordati Industria Chimica e Farmaceutica SpA?
Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide.
Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology.
Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions.
Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia).
Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative.
In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers.
In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA ir viens no populārākajiem uzņēmumiem vietnē Eulerpool.com.Akcienu ieguldījumu plāni piedāvā investoriem pievilcīgu iespēju ilgtermiņā uzkrāt kapitālu. Viens no galvenajiem priekšrocībām ir tā sauktais Vidējās izmaksas efekts: ieguldot regulāri noteiktu summu akcijās vai akciju fondos, automātiski tiek iegādāts vairāk daļu, kad cenas ir zemas, un mazāk, kad tās ir augstas. Tas laika gaitā var novest pie izdevīgākas vidējās cenas par daļu. Turklāt akcienu ieguldījumu plāni nodrošina piekļuvi dārgām akcijām arī mazajiem investoriem, jo tiem var pievienoties jau ar nelielām summu. Regulāra ieguldījumu veikšana arī veicina disciplinētu ieguldījumu stratēģiju un palīdz izvairīties no emocionāliem lēmumiem, piemēram, impulsīvas pirkšanas vai pārdošanas. Turklāt investori gūst labumu no potenciālās akciju vērtības pieauguma un no dividendēm, kuras var reinvestēt, tādejādi pastiprinot procentu uz procentu efektu un līdz ar to investētā kapitāla augšanu.